Illumina, Inc. (0J8Z.L)
USD 137.9
(-3.76%)
USD 137.9
(-3.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -608 Million USD | -92.59% |
| 2022 | -3.91 Billion USD | 4073.17% |
| 2021 | 747 Million USD | -121.21% |
| 2020 | 767 Million USD | -41.12% |
| 2019 | 1.17 Billion USD | 11.55% |
| 2018 | 1.06 Billion USD | 45.71% |
| 2017 | 780 Million USD | 6.13% |
| 2016 | 735.27 Million USD | -9.84% |
| 2015 | 751.68 Million USD | 70.25% |
| 2014 | 604.74 Million USD | -0.55% |
| 2013 | 363.62 Million USD | 19.8% |
| 2012 | 324.17 Million USD | 9.96% |
| 2011 | 236.09 Million USD | 19.36% |
| 2010 | 251.98 Million USD | 53.57% |
| 2009 | 169.02 Million USD | -4.82% |
| 2008 | 122.59 Million USD | -56.7% |
| 2007 | 18.01 Million USD | 763.86% |
| 2006 | 37.81 Million USD | 207.56% |
| 2005 | -5.51 Million USD | 400.04% |
| 2004 | -4.71 Million USD | 74.42% |
| 2003 | -19.19 Million USD | 24.15% |
| 2002 | -32.35 Million USD | -7.75% |
| 2001 | -22.55 Million USD | -40.62% |
| 2000 | -16.04 Million USD | -229.76% |
| 1999 | -4.86 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 589 Million USD | -10988.24% |
| 2024 Q3 | 741 Million USD | 144.62% |
| 2024 Q1 | 49 Million USD | 139.53% |
| 2023 Q4 | 50 Million USD | -94.36% |
| 2023 FY | - USD | -92.59% |
| 2023 Q1 | -64 Million USD | 24.71% |
| 2023 Q2 | -64 Million USD | 0.0% |
| 2023 Q3 | 886 Million USD | 1484.38% |
| 2022 Q4 | -85 Million USD | -102.05% |
| 2022 FY | - USD | 4073.17% |
| 2022 Q1 | 237 Million USD | 478.05% |
| 2022 Q2 | 72 Million USD | -69.62% |
| 2022 Q3 | 4.14 Billion USD | 5662.5% |
| 2021 Q3 | -545 Million USD | -391.44% |
| 2021 Q4 | 41 Million USD | 107.52% |
| 2021 FY | - USD | -121.21% |
| 2021 Q1 | 193 Million USD | 46.21% |
| 2021 Q2 | 187 Million USD | -3.11% |
| 2020 Q3 | 162 Million USD | 68.75% |
| 2020 Q4 | 132 Million USD | -18.52% |
| 2020 Q1 | 189 Million USD | -29.48% |
| 2020 Q2 | 96 Million USD | -49.21% |
| 2020 FY | - USD | -41.12% |
| 2019 Q4 | 268 Million USD | -12.99% |
| 2019 FY | - USD | 11.55% |
| 2019 Q3 | 308 Million USD | 50.24% |
| 2019 Q2 | 205 Million USD | 0.49% |
| 2019 Q1 | 204 Million USD | 3.55% |
| 2018 Q4 | 197 Million USD | -18.26% |
| 2018 Q3 | 241 Million USD | 6.17% |
| 2018 FY | - USD | 45.71% |
| 2018 Q1 | 218 Million USD | -5.22% |
| 2018 Q2 | 227 Million USD | 4.13% |
| 2017 Q1 | 60 Million USD | -58.29% |
| 2017 Q3 | 181 Million USD | 42.52% |
| 2017 Q4 | 230 Million USD | 27.07% |
| 2017 FY | - USD | 6.13% |
| 2017 Q2 | 127 Million USD | 111.67% |
| 2016 Q1 | 126.2 Million USD | -17.79% |
| 2016 Q2 | 139.49 Million USD | 10.53% |
| 2016 FY | - USD | -9.84% |
| 2016 Q3 | 161.47 Million USD | 15.76% |
| 2016 Q4 | 143.85 Million USD | -10.91% |
| 2015 FY | - USD | 70.25% |
| 2015 Q3 | 162.54 Million USD | 1.88% |
| 2015 Q4 | 153.52 Million USD | -5.55% |
| 2015 Q1 | 157.75 Million USD | 329.24% |
| 2015 Q2 | 159.55 Million USD | 1.14% |
| 2014 Q1 | 91.26 Million USD | 34.3% |
| 2014 Q2 | 105.57 Million USD | 15.68% |
| 2014 Q3 | 138.44 Million USD | 31.14% |
| 2014 FY | - USD | -0.55% |
| 2014 Q4 | 36.75 Million USD | -73.46% |
| 2013 Q1 | 190.68 Million USD | 155.25% |
| 2013 Q3 | 41.26 Million USD | -44.38% |
| 2013 Q4 | 67.95 Million USD | 64.67% |
| 2013 FY | - USD | 19.8% |
| 2013 Q2 | 74.19 Million USD | -61.09% |
| 2012 FY | - USD | 9.96% |
| 2012 Q4 | 74.7 Million USD | 39.52% |
| 2012 Q1 | 67.66 Million USD | 24.13% |
| 2012 Q3 | 53.54 Million USD | -2.08% |
| 2012 Q2 | 54.68 Million USD | -19.19% |
| 2011 Q2 | 92.53 Million USD | -9.96% |
| 2011 Q4 | 54.51 Million USD | 34.47% |
| 2011 FY | - USD | 19.36% |
| 2011 Q3 | 40.54 Million USD | -56.19% |
| 2011 Q1 | 102.76 Million USD | 27.09% |
| 2010 Q2 | 50.5 Million USD | 24.92% |
| 2010 Q3 | 60.12 Million USD | 19.05% |
| 2010 Q4 | 80.86 Million USD | 34.49% |
| 2010 FY | - USD | 53.57% |
| 2010 Q1 | 40.42 Million USD | -24.16% |
| 2009 Q4 | 53.3 Million USD | 58.56% |
| 2009 Q2 | 37.77 Million USD | -9.5% |
| 2009 Q1 | 41.73 Million USD | -7.27% |
| 2009 FY | - USD | -4.82% |
| 2009 Q3 | 33.61 Million USD | -10.99% |
| 2008 Q4 | 45.01 Million USD | -21.64% |
| 2008 Q2 | 34.86 Million USD | 36.91% |
| 2008 Q3 | 57.43 Million USD | 64.77% |
| 2008 FY | - USD | -56.7% |
| 2008 Q1 | 25.46 Million USD | -1.98% |
| 2007 Q4 | 25.97 Million USD | 33.75% |
| 2007 Q3 | 19.42 Million USD | 19.97% |
| 2007 Q2 | 16.18 Million USD | -94.85% |
| 2007 FY | - USD | 763.86% |
| 2007 Q1 | 314.36 Million USD | 1613.45% |
| 2006 Q3 | 16.81 Million USD | 113.2% |
| 2006 FY | - USD | 207.56% |
| 2006 Q4 | 18.34 Million USD | 9.08% |
| 2006 Q2 | 7.88 Million USD | 1596.56% |
| 2006 Q1 | 465 Thousand USD | -68.24% |
| 2005 Q1 | -619 Thousand USD | -210.34% |
| 2005 Q2 | 13.86 Million USD | 2339.1% |
| 2005 Q3 | -555 Thousand USD | -104.0% |
| 2005 Q4 | 1.46 Million USD | 363.78% |
| 2005 FY | - USD | 400.04% |
| 2004 Q2 | -1.71 Million USD | -9.75% |
| 2004 Q4 | 561 Thousand USD | 127.95% |
| 2004 Q3 | -2 Million USD | -17.3% |
| 2004 Q1 | -1.55 Million USD | 21.46% |
| 2004 FY | - USD | 74.42% |
| 2003 Q3 | -3.6 Million USD | 46.04% |
| 2003 Q4 | -2.17 Million USD | 41.82% |
| 2003 FY | - USD | 24.15% |
| 2003 Q1 | -6.9 Million USD | 91.59% |
| 2003 Q2 | -6.51 Million USD | 5.84% |
| 2002 Q3 | 13.82 Million USD | 307.46% |
| 2002 FY | - USD | -7.75% |
| 2002 Q2 | -14.44 Million USD | -2.28% |
| 2002 Q1 | -6.59 Million USD | 4.12% |
| 2002 Q4 | -80.03 Million USD | -670.78% |
| 2001 Q1 | -4.89 Million USD | -5.61% |
| 2001 FY | - USD | -40.62% |
| 2001 Q4 | -6.87 Million USD | -29.23% |
| 2001 Q3 | -5.32 Million USD | 2.65% |
| 2001 Q2 | -5.46 Million USD | -11.74% |
| 2000 FY | - USD | -229.76% |
| 2000 Q3 | -3.4 Million USD | 11.4% |
| 2000 Q1 | -4.16 Million USD | 0.0% |
| 2000 Q2 | -3.84 Million USD | 7.69% |
| 2000 Q4 | -4.63 Million USD | -36.06% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -272.739% |
| Dynavax Technologies Corporation | 9.66 Million USD | 6390.089% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 718.754% |
| Perrigo Company plc | 646.2 Million USD | 194.089% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 105.63% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | -35.408% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 94.609% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 118.673% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -485.787% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 113.063% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -1530.77% |
| Waters Corporation | 1.02 Billion USD | 159.477% |
| Biogen Inc. | 2.37 Billion USD | 125.578% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -595.437% |
| Evolus, Inc. | -41.81 Million USD | -1354.198% |
| Adicet Bio, Inc. | -136.53 Million USD | -345.307% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -416.787% |
| bluebird bio, Inc. | -167.16 Million USD | -263.721% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -305.042% |
| FibroGen, Inc. | -261.4 Million USD | -132.589% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 136.255% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -1268.238% |
| Homology Medicines, Inc. | -47.75 Million USD | -1173.138% |
| Geron Corporation | -174.78 Million USD | -247.862% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -166.525% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -560.303% |
| Myriad Genetics, Inc. | -67.8 Million USD | -796.755% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -503.013% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | -20.083% |
| Zoetis Inc. | 3.68 Billion USD | 116.499% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -1102.246% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 152.232% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 295.95% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 113.202% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -1585.051% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -164.336% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -128.574% |
| Verastem, Inc. | -83.16 Million USD | -631.068% |
| Nektar Therapeutics | -243.1 Million USD | -150.096% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -170.233% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -591.027% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | -38.435% |
| OPKO Health, Inc. | -65.51 Million USD | -828.018% |
| Exelixis, Inc. | 196.6 Million USD | 409.254% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 246.119% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 661.279% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -990.466% |
| uniQure N.V. | -253.1 Million USD | -140.221% |
| Imunon, Inc. | -20.78 Million USD | -2825.57% |
| Blueprint Medicines Corporation | -474.61 Million USD | -28.105% |
| Insmed Incorporated | -654.73 Million USD | 7.139% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 234.529% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | -75.995% |
| TG Therapeutics, Inc. | 26.1 Million USD | 2429.502% |
| Incyte Corporation | 919.42 Million USD | 166.128% |
| Emergent BioSolutions Inc. | -505.29 Million USD | -20.325% |